Baseline characteristics of study groups
| Variables | AbsSDP group (n=343) | FavOut group (n=418) | Overall ESPOIR cohort (n=813) |
| Age at RA onset (years) | 48.8±11.4 (50.9) | 48.3±11.6 (50.1) | 48.1±12.6 (50.1) |
| Female sex | 276 (80.5) | 325 (77.8) | 624 (76.8) |
| Smokers | 158 (46.1) | 198 (47.4) | 388 (47.7) |
| TJC at baseline (/28) | 9.2±7.2 (7.0) | 8.8±7.1 (7.0) | 8.4±7.0 (6.0) |
| SJC at baseline (/28) | 8.1±5.4 (7.0) | 7.8±5.4 (6.0) | 7.2±5.4 (6.0) |
| Extra-articular involvement at baseline | 198 (57.7) | 233 (55.7) | 444 (55.9) |
| DAS28-ESR at baseline | 5.2±1.3 (5.1) | 5.2±1.3 (5.1) | 5.1±1.3 (5.1) |
| HAQ-DI at baseline | 1.0±0.7 (0.9) | 1.0±0.7 (0.9) | 1.0±0.7 (0.9) |
| RF IgM-positive | 186 (54.2) | 237 (56.7) | 372 (45.8) |
| ACPA-positive | 170 (49.6) | 220 (52.6) | 315 (38.8) |
| ESR at baseline (mm at 1 hour) | 29.0±25.2 (22.0) | 29.4±25.3 (22.0) | 29.4±24.6 (22.0) |
| CRP at baseline (mg/L) | 20.0±29.7 (9.0) | 21.9±35.0 (9.0) | 22.2±33.6 (9.0) |
| Erosion at baseline | 88 (25.7) | 110 (26.3) | 185 (25.1) |
| Total vSHS at baseline | 2.9±4.9 (1.3) | 2.7±4.7 (1.3) | 2.8±5.0 (1.3) |
Data are means±SD (median), or n (%).
.AbsSDP, absence of structural damage progression; ACPA, anticitrullinated peptide antibody; CRP, C reactive protein; DAS28, Disease Activity Score in 28 Joints; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes; ESR, erythrocyte sedimentation rate; FavOut, favourable outcome; HAQ-DI, Health Assessment Questionnaire Disability Index; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; vSHS, Sharp-van der Heijde Score.